Dr. Brian Bressler

Gastroenterologist · Vancouver, British Columbia
  • 5 Emerging Treatments
  • 89 Publications

Dr. Brian Bressler is a Clinical Assistant Professor of Medicine in the Division of Gastroenterology at the University of British Columbia Department of Medicine. Having received his MD from the University of British Columbia, Dr. Bressler completed his residency at the Internal Medicine and Gastroenterology at the University of Toronto, after which he received an MS in Epidemiology from the Harvard Public School of Health and an Advanced Fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital, Harvard Medical School.

Following his advanced training at Harvard Medical School, Dr. Bressler has continued to treat patients, educate students and shares his insights with fellow gastroenterologists at patient education events. He is also a member of the GI Research Institute in Vancouver, one of the most active gastroenterology research centers in North America.

"Participating in a clinical trial can offer you an opportunity that really can be better than anything else you have available. "
-Dr. Brian Bressler



Emerging Treatments Offered

Dr. Brian Bressler is currently investigating 5 new and emerging treatments in Vancouver, British Columbia. New treatments are being studied to see if they will be safer and more effective than the current treatments available.

Limited to 1580 Patients

Stopping 5-ASA Therapy in Inactive Crohn's Disease

Robarts clinical trials inc.
Dr. Brian Bressler Dr. Brian Bressler

Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by diarrhea and
abdominal pain. Treatments include:

o 5-aminosalicylates, also known as 5-ASA (e.g. Asacol, Pentasa, Mezavant, Salofalk, and
Salazopyrin)
o Steroids (e.g. Entocort, prednisone)
o Immunomodulators (e.g. Imuran, Purinethol, Rheumatrex)
o Biologics (e.g. Remicade, Humira, Entyvio)

5-ASAs are the most commonly prescribed drug class for CD however there is uncertainty regarding their effectiveness for treating CD. Despite this, doctors continue to prescribe a potentially ineffective treatment which, aside from costs ($23M in Canada/year), possibly delays the use of more effective treatments that could reduce the risk of preventable complications in patients, such as surgery.

The STATIC study is trying to determine if patients who stop taking their 5-ASA do no worse than those who continue taking their 5-ASA. Participants will be monitored for complications, surgeries or hospitalizations. The results of this study have potential to improve the lives of patients, change physician prescribing practice, and reduce health care costs.

Limited to 1150 Patients

Etrolizumab for Crohn's Disease

Roche
Dr. Brian Bressler Dr. Brian Bressler

This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe Crohn's disease.

Limited to 200 Patients

Vedolizumab for Pouchitis

Takeda pharmaceutical company
Dr. Brian Bressler Dr. Brian Bressler

Vedolizumab is an intraveneous medication for ulcerative colitis who have had bowel surgery involving a proctocolectomy and ileal pouch anal anastomosis.

Limited to 800 Patients

Etrolizumab for Ulcerative Colitis (For patients who have previously used anti-TNFs)

Roche
Dr. Brian Bressler Dr. Brian Bressler

This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have failed an anti-TNF therapy (e.g. Remicade, Humira, etc.) previously.

Limited to 350 Patients

Etrolizumab for Ulcerative Colitis (TNF Inhibitors Naive)

Roche
Dr. Brian Bressler Dr. Brian Bressler

This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have not tried an anti-TNF therapy (e.g. Remicade, Humira, etc.).


Experience

Chief Medical Officer

Discover Therapies · 2016 - Present

Dt logo square transparent cropped

Our mission is to transform patients’ access to new treatment options to improve their health and accelerate research to find cures. The search for new treatments and cures progresses at a glacial pace, starving many patients of the opportunity to have better treatments and cures in their lifetime. We are changing this by connecting patients with the cutting-edge treatments options that are available to them through research. By making this connection simple for patients and simple for researchers, we will find cures faster. Our passion for empowering patients, our decades of experience in clinical research and our expertise with technology are enabling us to break down the barriers in research. With a community of over 30,000 patients and researchers rallying with us, we are not the only ones excited about our mission.

Director, Advanced IBD Training Program

University of British Columbia · 2007 - Present

Ubc

Clinical Associate Professor of Medicine, Division of Gastroenterology

Gastroenterologist

Providence Health Care · 2007 - Present

Providence health care

Member

GI Research Institute and Pacific Gastroenterology · 2005 - Present

The Gastrointestinal (GI) Clinic at St. Paul’s provides endoscopic procedures on an outpatient, inpatient, and emergency basis. It is supported by gastroenterology and colorectal surgery. The clinic performs over 9,000 standard and specialized procedures each year.

Scientific Advisory Board

Qu Biologics · 2005 - Present

Qu biologics

Qu Biologics was founded in 2007 by physician Dr. Hal Gunn and businessman and cancer survivor Rob Freeman. The company’s vision began with a desire to develop treatments that re-establish health by restoring the body’s normal immune function and innate capacity to heal. This vision continues to guide us today. Qu Biologics’ Site Specific Immunomodulators (SSIs) are designed to stimulate activated innate immune cell recruitment to the targeted organ or tissue to restore immune function and treat a range of chronic diseases, including cancer and inflammatory bowel disease.


Education

Graduate

University of British Columbia Department of Medicine · 2009

University of british columbia department of medicine

Advanced Inflammatory Bowel Disease Fellowship

Harvard Medical School - Massachusetts General Hospital · 2006

Harvard medical school

Epidemiology

Harvard Medical School · 2004 - 2005

Harvard medical school

Fellowship, Gastroenterology

University of Toronto · 2002 - 2005

University of toronto


Publications

Dr. Brian Bressler has been involved in 89 publications. View publications ›


Locations

Dr. Brian Bressler is affiliated with GI Research Institute at Suite 770-1190 Hornby Street, Vancouver BC .

Get Involved

Answer a few questions to see if this new treatment is right for you.

Join Now